Evidence map›Paper›PMID 37452880›Full record

ArticleRheumatology international2023

Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey.

M Weiss, M T Holzer, F Muehlensiepen, Y Ignatyev, C Fiehn, J Bauhammer, J Schmidt, S Schlüter, A Dihkan, D Scheibner and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Digital Approaches for Myositis.Current rheumatology reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 4 countries.

M Weiss *Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-6406-831X
M T Holzer *III. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.holzer@uke.de.ORCID 0000-0002-2064-6728
F MuehlensiepenFaculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany.ORCID 0000-0001-8571-7286
Y IgnatyevFaculty of Health Sciences, Center for Health Services Research, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany.ORCID 0000-0002-3573-7980
C FiehnPraxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany.ORCID 0000-0001-9665-1526
J BauhammerPraxis für Rheumatologie, Klinische Immunologie, Medical Center, Baden-Baden, Germany.ORCID 0000-0002-3336-0892
J SchmidtFaculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany.ORCID 0000-0002-5589-2371
S SchlüterMyositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany.
A DihkanThe Swedish Working Group for Myositis, The Swedish Rheumatism Association, Stockholm, Sweden.
D ScheibnerMyositis-Gruppe, Deutsche Gesellschaft Für Muskelkranke, Freiburg, Germany.
U SchneiderDepartment of Rheumatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-9117-3307
L Valor-MendezDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-4872-3502
G CorteDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
L GuptaDepartment of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.ORCID 0000-0003-2753-2990
H ChinoyDepartment of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.ORCID 0000-0001-6492-1288
I LundbergDivision of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden.ORCID 0000-0002-6068-9212
L CavagnaRheumatology Division, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.ORCID 0000-0003-3292-1528
J H W DistlerDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-7408-9333
G SchettDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-8740-9615
J KnitzaDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0001-9695-0657
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEMedizinische Hochschule Brandenburg Theodor Fontane · DEDeutsche Gesellschaft für Muskelkranke · DEHumboldt-Universität zu Berlin · DEIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska University Hospital · SEManchester Academic Health Science Centre · GBSandwell & West Birmingham Hospitals NHS Trust · GBSwedish Rheumatism Association · SEUniversität Hamburg · DE

Funding

Deutsche Forschungsgemeinschaft FOR2886
6 · The paper itself

Abstract

Antisynthease syndrome (ASSD) is a rare, complex and understudied autoimmune disease. Internet-based studies can overcome barriers of traditional on-site research and are therefore very appealing for rare diseases. The aim of this study was to investigate patient-reported symptoms, diagnostic delay, symptoms, medical care, health status, working status, disease knowledge and willingness to participate in research of ASSD patients by conducting an international web-based survey. The multilingual questionnaire was created by an international group of rheumatologists and patients and distributed online. 236 participants from 22 countries completed the survey. 184/236 (78.0%) were female, mean age (SD) was 49.6 years (11.3) and most common antisynthetase antibody was Jo-1 (169/236, 71.6%). 79/236 (33.5%) reported to work full-time. Median diagnostic delay was one year. The most common symptom at disease onset was fatigue 159/236 (67.4%), followed by myalgia 130/236 (55.1%). The complete triad of myositis, arthritis and lung involvement verified by a clinician was present in 42/236 (17.8%) at disease onset and in 88/236 (37.3%) during the disease course. 36/236 (15.3%) reported to have been diagnosed with fibromyalgia and 40/236 (16.3%) with depression. The most reported immunosuppressive treatments were oral corticosteroids 179/236 (75.9%), followed by rituximab 85/236 (36.0%). 73/236 (30.9%) had received physiotherapy treatment. 71/236 (30.1%) reported to know useful online information sources related to ASSD. 223/236 (94.5%) were willing to share health data for research purposes once a year. Our results reiterate that internet-based research is invaluable for cooperating with patients to foster knowledge in rare diseases.

Indexed as

AutoantibodiesMyositisDelayed DiagnosisFemaleHumansMaleMiddle AgedPatient Acceptance of Health CareRare DiseasesSyndromeAutoantibodiesAutoantibodiesDiagnosisHealth services researchMyositisTherapeutics

Identifiers

PMID37452880
PMCPMC10435645
OpenAlexW4384407397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.